BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 9718761)

  • 1. [Recombinant human erythropoietin in anemia associated with pediatric cancer: study of the identification of predictors of response].
    León Molinari P; Jiménez Monteagudo M; Barona Zamora P; Riol Diego M; Castro Paz L; Sierrasesúmaga Ariznavarreta L
    An Esp Pediatr; 1998 Jul; 49(1):17-22. PubMed ID: 9718761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy.
    Henry DH; Brooks BJ; Case DC; Fishkin E; Jacobson R; Keller AM; Kugler J; Moore J; Silver RT; Storniolo AM; Abels RI; Gordon DS; Nelson R; Larholt K; Bryant E; Rudnick S
    Cancer J Sci Am; 1995; 1(4):252-60. PubMed ID: 9166485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human erythropoietin in the treatment of cancer-related or chemotherapy-induced anaemia in patients with solid tumours.
    Nowrousian MR
    Med Oncol; 1998 Aug; 15 Suppl 1():S19-28. PubMed ID: 9785333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant human erythropoietin treatment: investigational new drug protocol for the anemia of the acquired immunodeficiency syndrome. Overall results.
    Phair JP; Abels RI; McNeill MV; Sullivan DJ
    Arch Intern Med; 1993 Dec; 153(23):2669-75. PubMed ID: 8250662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
    Voravud N; Sriuranpong V
    J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response predicting factors to recombinant human erythropoietin in cancer patients undergoing platinum-based chemotherapy.
    González-Barón M; Ordóñez A; Franquesa R; Constenla M; Montalar J; Gili F; Camps C; Sancho JF; Pérez-Cachot P
    Cancer; 2002 Dec; 95(11):2408-13. PubMed ID: 12436449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant human erythropoietin beta therapy: an effective strategy to reduce transfusion requirement in children receiving anticancer treatment.
    Corapcioglu F; Aksu G; Basar EZ; Demirel A; Oncel S; Mutlu A
    Pediatr Hematol Oncol; 2008 Sep; 25(6):509-21. PubMed ID: 18728970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
    Voravud N; Sriuranpong V; Suwanrusme H
    J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-weekly dosing of epoetin-alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy.
    Shasha D; George MJ; Harrison LB
    Cancer; 2003 Sep; 98(5):1072-9. PubMed ID: 12942577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythropoietin reduces anemia and transfusions after chemotherapy with paclitaxel and carboplatin.
    Dunphy FR; Dunleavy TL; Harrison BR; Boyd JH; Varvares MA; Dunphy CH; Rodriguez JJ; McDonough EM; Minster JR; McGrady MD
    Cancer; 1997 Apr; 79(8):1623-8. PubMed ID: 9118049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early intervention with epoetin alfa during platinum-based chemotherapy: an analysis of the results of a multicenter, randomized, controlled trial based on initial hemoglobin level.
    Savonije JH; van Groeningen CJ; Wormhoudt LW; Giaccone G
    Oncologist; 2006 Feb; 11(2):206-16. PubMed ID: 16476841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy of weekly epoetin Beta in the treatment of chemotherapy-induced anemia in solid tumors].
    Oudard S; Quoix E; Jenabian A; Bergougnoux L; Chouahnia K; Ferrero JM; Misset JL; Spaëth D
    Therapie; 2009; 64(1):17-25. PubMed ID: 19463249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Recombinant human erythropoietin in the treatment of anemic patients undergoing chemotherapy for cancer].
    Bösze P; Mayer A; Thurzó L; Kiss A; Rák K; Stumpf J
    Orv Hetil; 1995 Nov; 136(47):2567-72. PubMed ID: 8532322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of recombinant human erythropoietin in critically ill patients admitted to a long-term acute care facility: a randomized, double-blind, placebo-controlled trial.
    Silver M; Corwin MJ; Bazan A; Gettinger A; Enny C; Corwin HL
    Crit Care Med; 2006 Sep; 34(9):2310-6. PubMed ID: 16878035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial.
    Klinger M; Arias M; Vargemezis V; Besarab A; Sulowicz W; Gerntholtz T; Ciechanowski K; Dougherty FC; Beyer U
    Am J Kidney Dis; 2007 Dec; 50(6):989-1000. PubMed ID: 18037099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study.
    Aapro M; Leonard RC; Barnadas A; Marangolo M; Untch M; Malamos N; Mayordomo J; Reichert D; Pedrini JL; Ukarma L; Scherhag A; Burger HU
    J Clin Oncol; 2008 Feb; 26(4):592-8. PubMed ID: 18235117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early intervention with epoetin beta prevents severe anaemia in patients with solid tumours receiving platinum-based chemotherapy: results of the NeoPrevent study.
    de Castro J; Ordóñez A; Isla D; Sánchez A; Arrivi A; Manzano JL; Barón MG
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):35-42. PubMed ID: 16874498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial.
    Auerbach M; Ballard H; Trout JR; McIlwain M; Ackerman A; Bahrain H; Balan S; Barker L; Rana J
    J Clin Oncol; 2004 Apr; 22(7):1301-7. PubMed ID: 15051778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epoetin Beta once-weekly therapy in anemic patients with solid tumors and non-myeloid hematological malignancies receiving chemotherapy.
    Spaëth D; Desablens B; Rodon P; Mennecier B; Oudard S; Moullet I; Ghomari K; Bergougnoux L; Bleuzen P; Jenabian A; Ifrah N
    Oncology; 2008; 74(1-2):112-8. PubMed ID: 18547966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.
    Patton J; Kuzur M; Liggett W; Miranda F; Varsos H; Porter L
    Oncologist; 2004; 9(1):90-6. PubMed ID: 14755018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.